Press release
Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced new data that will be
About this update from Natera, Inc.
[{"type":"text","content":" AUSTIN, Texas--(BUSINESS WIRE)--\nNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced new data that will be presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI) in Barcelona, Spain. These presentations reinforce the strong clinical and economic utility of Signatera™ monitoring across colon and rectal cancers (CRC), as well as new clinical validation data on its tissue-free MRD assay.\n\n\nSignatera in CRC surveillance\n\n\nData on >3,000 CRC patients will be shared in an oral presentation, concluding that adding Signatera ctDNA* monitoring to the current standard of care in surveillance can better identify patients who are candidates for metastasis-directed therapy (MDT). Results indicated that Signatera-positive patients were up to 20x more likely to receive curative-intent MDT than Signatera-negative patients. By comparison, CEA positivity led to only a 2x increase, with no added value in stage IV.\n\n\nSignatera Genome in rectal cancer\n\n\nAn analysis will be presented from the MD Anderson INTERCEPT study (n=31) that used serial Signatera Genome testing in patients with locally advanced rectal cancer after neoadjuvant therapy. Results demonstrated 100% specificity/PPV, with surveillance sensitivity of 100% in the surgical cohort and 88% (7/8) overall.\n\n\nEconomic utility of Signatera-guided therapy in adjuvant CRC\n\n\nA budget impact model from BUPA, a multinational health insurance provider with over 60 million customers, will outline a 43% expected reduction in healthcare costs using Signatera-guided adjuvant treatment versus standard of care in stage II-III CRC.\n\n\n“We’re excited to present these new findings that continue to support the utility of Natera’s products across GI cancers,” said Adham Jurdi, M.D., senior medical director of oncology at Natera. “These data highlight our commitment to improving outcomes and driving innovation in MRD detection.”\n\n\nFull list of data featuring Natera’s technology at ESMO GI:\n\n\nJuly 4, 16:40-16:50 CET | FPN: 20 | Signatera (Oral Presentation)\nPresenter: Arvind Dasari, M.D., MS\nClinical utility of including circulating tumor DNA (ctDNA) monitoring in standard of care (SoC) colorectal cancer (CRC) surveillance\n\n\nJuly 4, 16:50-17:00 CET | FPN: 30 | Signatera (Oral Presentation)\nPresenter: Hideaki...